NCT06673212

Brief Summary

Sustained postprandial hyperglycaemia is an independent risk factor for cardiovascular complications and death. Intensive glucose control is the predominant factor to prevent the development of chronic complications in Type 2 Diabetes Mellitus (T2DM). The investigators have shown that phytochemical-rich extracts (in this case anthocyanins and their derivatives) can attenuate glucose response and there is also strong evidence for the role of fibre. Here a selected barley line (rich in anthocyanins and (1,3;1,4)-β-glucan) will be compared to a control barley and control wheat in an acute human dietary intervention (with n=15 healthy volunteers) to explore the potential to modulate postprandial glycaemia and insulinaenemia. An additional secondary outcome will include metabolomics analysis of the blood plasma and urine to detect differences in bioactive compounds including phytochemical metabolites. This will help ensure that barley lines being bred for human food can also deliver benefits for health.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable type-2-diabetes

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 27, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2023

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 28, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 4, 2024

Completed
Last Updated

November 12, 2024

Status Verified

November 1, 2024

Enrollment Period

10 months

First QC Date

October 31, 2024

Last Update Submit

November 7, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Postprandial blood glucose levels

    Modulation of postprandial blood glucose levels after acute consumption of the Black barley, Bere barley and the Wheat breads.

    5 hours

  • Postprandial insulin levels

    Modulation of postprandial insulin levels after acute consumption of the Black barley, Bere barley and the Wheat breads.

    5 hours

Secondary Outcomes (1)

  • Concentration of phytochemical metabolites in the systemic circulation

    5 hours

Study Arms (3)

Control Wheat Bread

ACTIVE COMPARATOR

Control Wheat Bread will be prepared to the same formulation as white wheat bread.

Other: Control Wheat Bread

Berneray Bere barley bread

EXPERIMENTAL

Berneray Bere barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Berneray Bere barley flour.

Other: Berneray Bere barley bread

Black Barley bread

EXPERIMENTAL

Black Barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Black Barley flour.

Other: Black Barley bread

Interventions

Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Control Wheat Bread

Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Berneray Bere barley bread

Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar

Black Barley bread

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Apparently healthy male and female subjects with Diabetes Risk Score ≥ 7 points

You may not qualify if:

  • Type 1 diabetes
  • Type 2 diabetes controlled with medication
  • Coeliac Disease
  • Eating disorders (anorexia, bulimia, binge eating or night eating syndrome)
  • Food allergies/intolerances
  • Any significant health issues
  • Breastfeeding/ Pregnancy
  • Addiction to any substances
  • Are unable to give written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Aberdeen, The Rowett Institute

Aberdeen, AB25 2ZD, United Kingdom

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Wendy Russell

    University of Aberdeen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2024

First Posted

November 4, 2024

Study Start

July 27, 2022

Primary Completion

May 15, 2023

Study Completion

June 28, 2024

Last Updated

November 12, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations